<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995147</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-0072</org_study_id>
    <nct_id>NCT03995147</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma</brief_title>
  <official_title>Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will research untreated non-germinal center diffuse large B cell lymphoma and what
      causes the disease and the way patients respond to pembrolizumab combined with R-CHOP
      chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">August 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) rate when combining pembrolizumab with R-CHOP</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate after 6 cycles of pembrolizumab in combination with R-CHOP</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS) rate after 6 cycles of pembrolizumab in combination with R-CHOP</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rate after 6 cycles of pembrolizumab in combination with R-CHOP</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE v 4.0</measure>
    <time_frame>29 months</time_frame>
    <description>Safety and tolerability of pembrolizumab in combination with R-CHOP followed by Pembrolizumab.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>B Cell Lymphoma</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.
Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years).</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP Protocol</intervention_name>
    <description>R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/female participants who are at least 18 years of age on the day of signing
             informed consent with a histologically confirmed diagnosis of diffuse large B cell
             lymphoma or high-grade B cell lymphoma of a non-germinal center phenotype according to
             Hans criteria are eligible for enrollment in this study.

          2. International Prognostic Index (IPI) score of ≥ 3, or an age-adjusted (aa) IPI score
             of ≥ 2.

          3. A male participant must agree to use a contraception during the treatment period and
             for at least 120 days after the final dose of study treatment and refrain from
             donating sperm during this period.

          4. A female participant is eligible to participate if she is not pregnant, not
             breastfeeding, and at least one of the following conditions applies:

               1. Not a woman of childbearing potential (WOCBP) OR

               2. A WOCBP who agrees to follow the contraceptive guidance during the treatment
                  period and for at least 120 days after the last dose of study treatment.

          5. The participant (or legally acceptable representative if applicable) provides written
             informed consent for the trial.

          6. Have measurable disease with one or more measurable lymphoma lesions ( &gt;1.5 cm in the
             long axis and &gt;1.0 cm in the short axis).

          7. Patients must be able to provide an archived tumor tissue sample or newly obtained
             core or excisional biopsy of a tumor lesion.

          8. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          9. Have adequate organ function. See below for adequate organ function laboratory values:

               -  Hematological

                    -  Absolute neutrophil count (ANC) less or equal to 1000/microliter

                    -  Platelets less or equal to 100,000/microliters

                    -  Hemoglobin less or equal to 8.0/grams per decilitre

               -  Renal

                    -  Creatinine or Measured/calculated creatinine clearance (CrCl) greater or
                       equal to 1.5xULN or less than or equal to 30 mililiter per minute for
                       participants with creatinine levels less than 1.5xULN

               -  Hepatic

                    -  Total bilirubin greater than or equal to 1.5 x ULN or direct bilirubin
                       greater than or equal to ULN for participants with total bilirubin levels
                       less than 1.5 x ULN

                    -  AST (SGOT) and ALT (SGPT) greater than or equal to 2.5 x ULN (greater than
                       or equal to 2.5 x ULN for participants with liver involvement)

        Exclusion Criteria:

          1. Positive urine pregnancy test within 72 hours prior to the initiation of study
             treatment. If the urine test is positive or cannot be confirmed as negative, a serum
             pregnancy test will be required.

          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,
             OX-40, CD137).

          3. Has received prior anti-lymphoma therapy, including radiation therapy, chemotherapy,
             targeted therapy, or immunotherapy.

             Note: Prior corticosteroid treatment (&lt;10 days in duration) to alleviate
             lymphoma-elated symptoms is permitted.

             Note: If participant received major surgery, he or she must have recovered adequately
             from complications from the intervention prior to starting study treatment.

          4. Has received a live vaccine within 30 days prior to the first dose of study drug.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

          5. Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment.

          6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent, with the exception of
             short-term corticosteroid use to control lymphoma-related symptoms as outlined above)
             or any other form of immunosuppressive therapy within 7 days prior to the first dose
             of study drug.

          7. Has a known additional malignancy that is progressing or has required active treatment
             within the past 2 years. Note: Participants with basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,
             cervical cancer in situ) that have undergone potentially curative therapy are not
             excluded. Other exceptions may be permitted after discussion with the principal
             investigator.

          8. Has known active CNS involvement by lymphoma.

          9. Has a diagnosis of high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 gene
             rearrangements (double hit lymphoma), primary mediastinal lymphoma, gray zone
             lymphoma, composite lymphoma, or previously-untreated low-grade lymphoma with disease
             transformation to DLBCL.

         10. Has severe hypersensitivity (≥ grade 3) to pembrolizumab and/or any of its excipients.

         11. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

         12. Has a history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

         13. Has an active infection requiring systemic therapy.

         14. Has a known history of Human Immunodeficiency Virus (HIV) infection.

         15. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive, Hepatitis B core [HBc] antibody total reactive, or HBV virus detected) or
             known active Hepatitis C virus infection (defined as HCV RNA is detected). Note: All
             patients will be screened for prior Hepatitis B exposure prior to starting therapy.
             Hepatitis C testing is not required.

         16. Has a known history of, or active infection with tuberculosis.

         17. Has a history of solid organ transplantation.

         18. Has a left ventricular ejection fraction &lt; 45%, myocardial infarction within 6 months
             of initiating study treatment, New York Heart Assocation class III/IV heart failure,
             or any uncontrolled cardiovascular conditions.

         19. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the subject's
             participation for the full duration of the study, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         20. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         21. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of trial treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Kline, MD</last_name>
    <phone>773-702-5550</phone>
    <email>jkline@medicine.bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Kline, MD</last_name>
      <phone>773-702-5550</phone>
      <email>jkline@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Justin Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

